Eris Lifesciences Limited (ERIS) - Net Assets
Based on the latest financial reports, Eris Lifesciences Limited (ERIS) has net assets worth Rs35.03 Billion INR (≈ $378.89 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs71.60 Billion ≈ $774.32 Million USD) and total liabilities (Rs36.56 Billion ≈ $395.43 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Eris Lifesciences Limited total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs35.03 Billion |
| % of Total Assets | 48.93% |
| Annual Growth Rate | 37.34% |
| 5-Year Change | 107.54% |
| 10-Year Change | 909.67% |
| Growth Volatility | 28.83 |
Eris Lifesciences Limited - Net Assets Trend (2012–2025)
This chart illustrates how Eris Lifesciences Limited's net assets have evolved over time, based on quarterly financial data. Check ERIS tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Eris Lifesciences Limited (2012–2025)
The table below shows the annual net assets of Eris Lifesciences Limited from 2012 to 2025. For live valuation and market cap data, see ERIS market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs32.72 Billion ≈ $353.83 Million |
+1.54% |
| 2024-03-31 | Rs32.22 Billion ≈ $348.45 Million |
+45.09% |
| 2023-03-31 | Rs22.21 Billion ≈ $240.16 Million |
+16.38% |
| 2022-03-31 | Rs19.08 Billion ≈ $206.36 Million |
+21.05% |
| 2021-03-31 | Rs15.76 Billion ≈ $170.48 Million |
+21.61% |
| 2020-03-31 | Rs12.96 Billion ≈ $140.19 Million |
+10.91% |
| 2019-03-31 | Rs11.69 Billion ≈ $126.40 Million |
+31.93% |
| 2018-03-31 | Rs8.86 Billion ≈ $95.81 Million |
+64.09% |
| 2017-03-31 | Rs5.40 Billion ≈ $58.39 Million |
+66.62% |
| 2016-03-31 | Rs3.24 Billion ≈ $35.04 Million |
+20.20% |
| 2015-03-31 | Rs2.70 Billion ≈ $29.16 Million |
+49.06% |
| 2014-03-31 | Rs1.81 Billion ≈ $19.56 Million |
+63.18% |
| 2013-03-31 | Rs1.11 Billion ≈ $11.99 Million |
+109.52% |
| 2012-03-31 | Rs528.98 Million ≈ $5.72 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Eris Lifesciences Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5748.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs27.93 Billion | 97.84% |
| Common Stock | Rs136.20 Million | 0.48% |
| Other Comprehensive Income | Rs186.40 Million | 0.65% |
| Other Components | Rs293.40 Million | 1.03% |
| Total Equity | Rs28.54 Billion | 100.00% |
Eris Lifesciences Limited Competitors by Market Cap
The table below lists competitors of Eris Lifesciences Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Blackbaud Inc
NASDAQ:BLKB
|
$2.04 Billion |
|
Changshu Tianyin Electromechan
SHE:300342
|
$2.04 Billion |
|
Polibeli Group Ltd Class A Ordinary Shares
NASDAQ:PLBL
|
$2.04 Billion |
|
Huaxia Eye Hospital Group Co. Ltd. A
SHE:301267
|
$2.04 Billion |
|
CSSC Steel Structure Engineering Co Ltd
SHG:600072
|
$2.04 Billion |
|
Select Medical Holdings
NYSE:SEM
|
$2.04 Billion |
|
Xiangtan Electric Manufacturing Co Ltd
SHG:600416
|
$2.03 Billion |
|
SF Diamond
SHE:300179
|
$2.03 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eris Lifesciences Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 25,861,190,000 to 28,543,600,000, a change of 2,682,410,000 (10.4%).
- Net income of 3,518,400,000 contributed positively to equity growth.
- Dividend payments of 1,000,500,000 reduced retained earnings.
- Share repurchases of 72,200,000 reduced equity.
- New share issuances of 72,200,000 increased equity.
- Other comprehensive income increased equity by 50,700,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs3.52 Billion | +12.33% |
| Dividends Paid | Rs1.00 Billion | -3.51% |
| Share Repurchases | Rs72.20 Million | -0.25% |
| Share Issuances | Rs72.20 Million | +0.25% |
| Other Comprehensive Income | Rs50.70 Million | +0.18% |
| Other Changes | Rs113.81 Million | +0.4% |
| Total Change | Rs- | 10.37% |
Book Value vs Market Value Analysis
This analysis compares Eris Lifesciences Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.61x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 397.14x to 6.61x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-03-31 | Rs3.48 | Rs1383.20 | x |
| 2013-03-31 | Rs7.72 | Rs1383.20 | x |
| 2014-03-31 | Rs12.84 | Rs1383.20 | x |
| 2015-03-31 | Rs19.32 | Rs1383.20 | x |
| 2016-03-31 | Rs23.33 | Rs1383.20 | x |
| 2017-03-31 | Rs39.27 | Rs1383.20 | x |
| 2018-03-31 | Rs62.64 | Rs1383.20 | x |
| 2019-03-31 | Rs83.59 | Rs1383.20 | x |
| 2020-03-31 | Rs94.41 | Rs1383.20 | x |
| 2021-03-31 | Rs116.01 | Rs1383.20 | x |
| 2022-03-31 | Rs140.41 | Rs1383.20 | x |
| 2023-03-31 | Rs161.27 | Rs1383.20 | x |
| 2024-03-31 | Rs189.92 | Rs1383.20 | x |
| 2025-03-31 | Rs209.39 | Rs1383.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eris Lifesciences Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.33%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.22%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 2.46x
- Recent ROE (12.33%) is below the historical average (33.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 77.14% | 13.49% | 2.68x | 2.13x | Rs321.54 Million |
| 2013 | 54.86% | 14.81% | 2.29x | 1.62x | Rs475.89 Million |
| 2014 | 39.90% | 13.84% | 1.88x | 1.53x | Rs527.69 Million |
| 2015 | 33.59% | 16.36% | 1.53x | 1.34x | Rs626.67 Million |
| 2016 | 41.63% | 22.37% | 1.43x | 1.30x | Rs1.01 Billion |
| 2017 | 44.84% | 33.39% | 1.13x | 1.19x | Rs1.88 Billion |
| 2018 | 34.15% | 34.37% | 0.59x | 1.70x | Rs2.08 Billion |
| 2019 | 25.28% | 30.07% | 0.62x | 1.35x | Rs1.76 Billion |
| 2020 | 22.87% | 28.02% | 0.68x | 1.20x | Rs1.67 Billion |
| 2021 | 22.53% | 29.78% | 0.65x | 1.16x | Rs1.97 Billion |
| 2022 | 21.28% | 30.62% | 0.58x | 1.19x | Rs2.15 Billion |
| 2023 | 17.40% | 23.00% | 0.45x | 1.67x | Rs1.63 Billion |
| 2024 | 15.16% | 19.68% | 0.28x | 2.73x | Rs1.33 Billion |
| 2025 | 12.33% | 12.22% | 0.41x | 2.46x | Rs664.04 Million |
Industry Comparison
This section compares Eris Lifesciences Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $27,240,259,507
- Average return on equity (ROE) among peers: 16.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eris Lifesciences Limited (ERIS) | Rs35.03 Billion | 77.14% | 1.04x | $2.04 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $1.17 Billion | 3.21% | 1.48x | $25.00 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.23 Billion | 12.93% | 2.27x | $401.98 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $15.58 Billion | 12.42% | 0.44x | $662.50 Million |
| Abbott India Limited (ABBOTINDIA) | $8.33 Billion | 20.02% | 0.37x | $6.41 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $8.41 Billion | 36.84% | 0.36x | $4.75 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.23 Billion | 13.11% | 3.52x | $1.13 Billion |
| Alkem Laboratories Limited (ALKEM) | $37.87 Billion | 19.58% | 0.46x | $7.38 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.26 Billion | 16.93% | 0.29x | $162.90 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $52.38 Billion | 9.95% | 0.36x | $1.71 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $138.92 Billion | 17.02% | 0.90x | $9.67 Billion |
About Eris Lifesciences Limited
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti"diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women… Read more